|
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS
|
30 May 2016 |
|
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
|
23 May 2016 |
|
New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
|
12 April 2016 |
|
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
|
24 March 2016 |
|
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable
|
25 January 2016 |
|
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia
|
19 January 2016 |
|
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
|
22 December 2015 |
|
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
|
26 November 2015 |
|
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years
|
12 November 2015 |
|
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
|
11 November 2015 |
|
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
|
22 September 2015 |
|
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes
|
17 September 2015 |
|
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
|
14 August 2015 |
|
Patients reporting better quality of communication by their physician show improved self-care
|
08 June 2015 |
|
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment
|
26 May 2015 |
|
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate
|
19 May 2015 |
|
Boehringer Ingelheim positioned for future growth with product launches
|
28 April 2015 |
|
New international survey of lung cancer oncologists highlights underutilization of personalized treatments
|
20 April 2015 |
|
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
|
20 November 2014 |
|
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
|
24 September 2014 |